144.65 0.00 (0.00%)
After hours: 5:07PM EST
|Bid||144.93 x 900|
|Ask||144.68 x 1000|
|Day's Range||144.06 - 146.74|
|52 Week Range||106.11 - 153.30|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 29, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||1.64 (1.13%)|
|1y Target Est||154.53|
SAN DIEGO, Nov. 8, 2019 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of McKesson Corporation (MCK) ("McKesson" or the "Company") against certain of its officers and directors. Recently, a class action lawsuit pending in the United States District Court for the Northern District of California against McKesson and certain of its executives survived Defendants' attempts to have the case dismissed. The case arises out of whether McKesson and certain of its executives made materially false and misleading statements and omissions regarding the Company's financial performance and its generics business.
Bay Area business leaders are rather vocal on why leaving the region makes sense for many entrepreneurs and investors.
McKesson Corp. reported Wednesday a fiscal second-quarter profit that matched expectations while revenue rose well above expectations, amid strength in its U.S. pharmaceutical and specialty solutions business. The stock was still inactive in premarket trading. For the quarter to Sept. 30, the health care and drug company swung to net loss of $730 million, or $3.99 a share, from income of $499 million, or $2.52 a share, in the year-ago period. Excluding non-recurring items, such as a $1.4 billion charge related to an impairment with the planned exit of its investment in Change Healthcare, adjusted EPS came to $3.60, which matched the FactSet consensus. Revenue rose 9% to $57.62 billion, above the FactSet consensus of $55.08 billion. U.S. pharmaceutical and specialty solutions revenue grew 10% to $46.0 billion, primarily because of price increases in branded pharmaceuticals and increased specialty pharmaceutical volume. European pharmaceutical revenue fell 1% to $6.6 billion and medical-surgical revenue increased 6% to $2.1 billion. The company affirmed its fiscal 2020 adjusted EPS guidance range of $14.00 to $14.60, which surrounds the FactSet consensus of $14.38. The stock has rallied 35.2% year to date, while the SPDR Health Care Select Sector ETF has advanced 9.0% and the S&P 500 has gained 21.1%.
IRVING, Texas-- -- Total revenues of $57.6 billion, reflecting 9% growth. Loss per diluted share of $ and Adjusted Earnings per diluted share of $3.60. Reaffirmed fiscal 2020 Adjusted EPS guidance range of $14.00 to $14.60. McKesson Corporation today reported results for the second quarter ended September 30, 2019. Fiscal 2020 Second-Quarter and Year-to-Date Result Summary Second Quarter Year-to-Date ...
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In the stock market you get paid from capital appreciation and dividends. Of the two, the only one with any certainty is dividends, explains blue chip stock expert Kelley Wright, editor of Investment Quality Trends.
The drug company Johnson & Johnson confirmed in an SEC filing on Wednesday night that it had reached an agreement in principle with four state attorneys general to settle all opioid claims against the company for $4 billion, and cut its previously-reported third quarter earnings to reflect the possible deal.
The Board of Directors of McKesson Corporation today declared a regular dividend of 41 cents per share of common stock. The dividend will be payable on January 2, 2020, to stockholders of record on December 2, 2019.
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Five drug companies announced a $48 billion deal after the close on Monday that aims to settle claims related to the opioid crisis in North Carolina, Pennsylvania, Tennessee and Texas.